Swiss biotechnology company

Serono

(SRA)

said it has hired Goldman Sachs as an adviser to help it consider strategic alternatives.

The company's statement came after a published report said Serono was looking into the possibility of merging with another firm.

Serono said there was no assurance a transaction will be completed. In 2004, worldwide revenue was $2.46 billion and net income was $494.2 million. The company's products are sold in more than 90 countries.

Shares of Serono were gaining $1.28, or 7.8%, to $17.72 in premarket trading Tuesday.